Literature DB >> 27346915

Switching and stopping antidepressants.

Nicholas Keks1, Judy Hope1, Simone Keogh2.   

Abstract

Switching from one antidepressant to another is frequently indicated due to an inadequate treatment response or unacceptable adverse effects. All antidepressant switches must be carried out cautiously and under close observation. Conservative switching strategies involve gradually tapering the first antidepressant followed by an adequate washout period before the new antidepressant is started. This can take a long time and include periods of no treatment with the risk of potentially life-threatening exacerbations of illness. Clinical expertise is needed for more rapid or cross-taper switching as drug toxicity, including serotonin syndrome, may result from inappropriate co-administration of antidepressants. Some antidepressants must not be combined. Antidepressants can cause withdrawal syndromes if discontinued abruptly after prolonged use. Relapse and exacerbation of depression can also occur. Gradual dose reduction over days to weeks reduces the risk and severity of complications.

Entities:  

Keywords:  antidepressant; drug interaction; drug withdrawal; serotonin syndrome

Year:  2016        PMID: 27346915      PMCID: PMC4919171          DOI: 10.18773/austprescr.2016.039

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  7 in total

1.  Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.

Authors:  Giovanni A Fava; Alessia Gatti; Carlotta Belaise; Jenny Guidi; Emanuela Offidani
Journal:  Psychother Psychosom       Date:  2015-02-21       Impact factor: 17.659

Review 2.  Strategies for switching antidepressants to achieve maximum efficacy adolescents.

Authors:  James W Jefferson
Journal:  J Clin Psychiatry       Date:  2008       Impact factor: 4.384

3.  Serotonin syndrome.

Authors:  Nicholas A Buckley; Andrew H Dawson; Geoffrey K Isbister
Journal:  BMJ       Date:  2014-02-19

Review 4.  Management of antidepressant-induced sexual dysfunction.

Authors:  Nicholas A Keks; Judy Hope; Christine Culhane
Journal:  Australas Psychiatry       Date:  2014-10-21       Impact factor: 1.369

5.  Switching antidepressant class does not improve response or remission in treatment-resistant depression.

Authors:  Daniel Souery; Alessandro Serretti; Raffaella Calati; Pierre Oswald; Isabelle Massat; Anastasios Konstantinidis; Sylvie Linotte; Joseph Bollen; Koen Demyttenaere; Siegfried Kasper; Yves Lecrubier; Stuart Montgomery; Joseph Zohar; Julien Mendlewicz
Journal:  J Clin Psychopharmacol       Date:  2011-08       Impact factor: 3.153

6.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

Authors:  A John Rush; Madhukar H Trivedi; Stephen R Wisniewski; Andrew A Nierenberg; Jonathan W Stewart; Diane Warden; George Niederehe; Michael E Thase; Philip W Lavori; Barry D Lebowitz; Patrick J McGrath; Jerrold F Rosenbaum; Harold A Sackeim; David J Kupfer; James Luther; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-11       Impact factor: 18.112

Review 7.  Treatment-resistant depression.

Authors:  Alison Little
Journal:  Am Fam Physician       Date:  2009-07-15       Impact factor: 3.292

  7 in total
  13 in total

Review 1.  Suicidality: prevention, detection and intervention.

Authors:  Josephine Anderson; Philip B Mitchell; Henry Brodaty
Journal:  Aust Prescr       Date:  2017-10-03

Review 2.  Practices Involved in the Enteral Delivery of Drugs.

Authors:  Kathryn S Bandy; Stephanie Albrecht; Bhavyata Parag; Stephen A McClave
Journal:  Curr Nutr Rep       Date:  2019-12

3.  Designing Flexible Longitudinal Regimens: Supporting Clinician Planning for Discontinuation of Psychiatric Drugs.

Authors:  Eunkyung Jo; Myeonghan Ryu; Georgia Kenderova; Samuel So; Bryan Shapiro; Alexandra Papoutsaki; Daniel A Epstein
Journal:  Proc SIGCHI Conf Hum Factor Comput Syst       Date:  2022-04-29

4.  Diving and mental health: the potential benefits and risks from a survey of recreational scuba divers.

Authors:  Marguerite St Leger Dowse; Ben Whalley; Matthew K Waterman; Robert M Conway; Gary R Smerdon
Journal:  Diving Hyperb Med       Date:  2019-12-20       Impact factor: 0.887

5.  Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001-2017.

Authors:  Johanna Seifert; Hannah B Maier; Fabienne Führmann; Stefan Bleich; Susanne Stübner; Marcel Sieberer; Xueqiong Bernegger; Waldemar Greil; Cornelius Schüle; Sermin Toto; Renate Grohmann; Matthias A Reinhard
Journal:  J Neural Transm (Vienna)       Date:  2022-05-07       Impact factor: 3.850

6.  Pharmacogenomics at the Point of Care: A Community Pharmacy Project in British Columbia.

Authors:  Samantha Breaux; Francis Arthur Derek Desrosiers; Mauricio Neira; Sunita Sinha; Corey Nislow
Journal:  J Pers Med       Date:  2020-12-24

7.  Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS).

Authors:  E Bothos; E Ntoumou; K Kelaidoni; D Roukas; N Drakoulis; M Papasavva; F A Karakostis; P Moulos; K Karakostis
Journal:  J Transl Med       Date:  2021-04-15       Impact factor: 5.531

8.  Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.

Authors:  Natalie T Mills; Emma Sampson; Célia Fourrier; Bernhard T Baune
Journal:  Int J Neuropsychopharmacol       Date:  2021-04-21       Impact factor: 5.176

9.  Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review.

Authors:  Marcin Siwek; Adrian Andrzej Chrobak; Aleksandra Gorostowicz; Anna Julia Krupa; Dominika Dudek
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11

10.  Antidepressants and suicidal behaviour in late life: a prospective population-based study of use patterns in new users aged 75 and above.

Authors:  Khedidja Hedna; Karolina Andersson Sundell; Armina Hamidi; Ingmar Skoog; Sara Gustavsson; Margda Waern
Journal:  Eur J Clin Pharmacol       Date:  2017-11-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.